Search

Displaying results 4161 - 4170 of 8517 in total
  1. Drug

    Peginterferon beta-1a

    go.drugbank.com/drugs/DB09122
    ApprovedInvestigational

    It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021.

  2. Drug

    Hydroxyamphetamine

    go.drugbank.com/drugs/DB09352
    Approved

    The main use of hydroxyamphetamines as eye drops is the diagnosis of Horner's syndrome which is characterized by nerve lesions. … Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test.

  3. Drug

    Anecortave acetate

    go.drugbank.com/drugs/DB05288
    Investigational

    As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.

  4. Drug

    Omega-6 fatty acids

    go.drugbank.com/drugs/DB13168
    InvestigationalNutraceutical

    They are a family of fatty acid molecules that act as precursors to potent lipid mediator signalling molecules with either pro-inflammatory and anti-inflammatory effects. … Cells involved in the inflammatory response are typically rich in the n-6 fatty acid arachidonic acid, as generally, eicosanoids derived from n-6 PUFA are pro-inflammatory.

  5. Drug

    Sesame oil

    go.drugbank.com/drugs/DB11172
    ApprovedNutraceutical

    It has also shown to accelerate alcohol decomposition in the liver [A27257]. Sesame oil is considered an indirect additive used in food cotact substances by the FDA.

  6. Drug

    Triheptanoin

    go.drugbank.com/drugs/DB11677
    ApprovedInvestigational

    [A214817] Triheptanoin was granted FDA approval on 30 June 2020.[L14612]

  7. Drug

    Donidalorsen

    go.drugbank.com/drugs/DB18751
    ApprovedInvestigational

    [L53788] Donidalorsen was approved by the FDA in August 2025 for prophylactic use to prevent HAE attacks.[L53783,L53788] It is the first RNA-targeted therapy approved for HAE.[L53783]

  8. Drug

    Diflunisal

    go.drugbank.com/drugs/DB00861
    Approved

    Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway.

  9. Drug

    Ammonia N-13

    go.drugbank.com/drugs/DB09326
    Approved

    The active ingredient, [13N] ammonia, has the molecular formula of 13NH3 with a molecular weight of 16.02.

  10. Drug

    Paltusotine

    go.drugbank.com/drugs/DB16277
    ApprovedInvestigational

    [A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061]